Nureca

  • Market Cap: Micro Cap
  • Industry: Healthcare Services
  • ISIN: INE0DSF01015
  • NSEID: NURECA
  • BSEID: 543264
INR
265.00
10 (3.92%)
BSENSE

Apr 10

BSE+NSE Vol: 13.32 k

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
{
  "main_header": {
    "sid": 1003462,
    "name": "Nureca",
    "stock_name": "Nureca",
    "full_name": "Nureca Ltd",
    "name_url": "stocks-analysis/nureca",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 1,
    "country_id": 34,
    "currency": "INR",
    "cmp": "265.00",
    "chg": 10,
    "chgp": "3.92%",
    "dir": 1,
    "prev_price": "255.00",
    "mcapval": "244.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 543264,
    "symbol": "NURECA",
    "ind_name": "Healthcare Services",
    "ind_code": 26,
    "indexname": "India SENSEX",
    "isin": "INE0DSF01015",
    "curr_date": "Apr 10",
    "curr_time": "",
    "bse_nse_vol": "13.32 k",
    "exc_status": "Active",
    "traded_date": "Apr 10, 2026",
    "traded_date_str": "2026 04 10",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/nureca-1003462-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Nureca Ltd Downgraded to Strong Sell Amid Bearish Technicals and Expensive Valuation",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/nureca-ltd-downgraded-to-strong-sell-amid-bearish-technicals-and-expensive-valuation-3936617",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/NurecaLtd_mojoScore_3936617.png",
        "date": "2026-04-08 08:26:52",
        "description": "Nureca Ltd, a micro-cap player in the Healthcare Services sector, has seen its investment rating downgraded from Sell to Strong Sell as of 7 April 2026. This shift reflects a confluence of deteriorating technical indicators, an expensive valuation profile, weak financial trends, and subpar quality metrics. The downgrade comes despite the company’s recent positive quarterly results, underscoring growing concerns about its longer-term fundamentals and market positioning."
      },
      {
        "title": "Nureca Ltd Forms Death Cross, Signalling Potential Bearish Trend",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/nureca-ltd-forms-death-cross-signalling-potential-bearish-trend-3936130",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/NurecaLtd_dealthcross_3936130.png",
        "date": "2026-04-07 18:00:41",
        "description": "Nureca Ltd, a micro-cap player in the Healthcare Services sector, has recently formed a Death Cross, a technical indicator where the 50-day moving average crosses below the 200-day moving average. This development signals a potential shift towards a bearish trend, reflecting deteriorating momentum and raising concerns about the stock’s medium to long-term outlook."
      },
      {
        "title": "Nureca Ltd Valuation Shifts Signal Price Attractiveness Concerns Amid Sector Challenges",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/nureca-ltd-valuation-shifts-signal-price-attractiveness-concerns-amid-sector-challenges-3933721",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/NurecaLtd_valuationdot_3933721.png",
        "date": "2026-04-06 08:01:36",
        "description": "Nureca Ltd, a micro-cap player in the healthcare services sector, has seen a notable shift in its valuation parameters, moving from fair to expensive territory. Despite a recent day gain of 5.87%, the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios now exceed historical and peer averages, raising questions about its price attractiveness amid subdued returns and deteriorating profitability metrics."
      },
      {
        "title": "Nureca Ltd is Rated Sell by MarketsMOJO",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/nureca-ltd-is-rated-sell-by-marketsmojo-3933044",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/NurecaLtd_mojoScore_3933044.png",
        "date": "2026-04-04 10:10:02",
        "description": "Nureca Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 09 March 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 04 April 2026, providing investors with the latest insights into the company’s fundamentals, valuation, financial trends, and technical outlook."
      },
      {
        "title": "Nureca Ltd Locks at Upper Circuit With 10% Gain — Buyers Queue, Sellers Absent",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/nureca-ltd-surges-to-upper-circuit-on-robust-buying-pressure-3928915",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/NurecaLtd_stocks_hitting_upper_circuit_3928915.png",
        "date": "2026-04-01 11:00:24",
        "description": "At Rs 227.42, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Nureca Ltd locked at its upper circuit of 10% on 1 Apr 2026, with buyers queuing and no sellers willing to part with shares."
      },
      {
        "title": "Nureca Ltd is Rated Sell by MarketsMOJO",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/nureca-ltd-is-rated-sell-by-marketsmojo-3909739",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/NurecaLtd_mojoScore_3909739.png",
        "date": "2026-03-24 10:10:29",
        "description": "Nureca Ltd is rated Sell by MarketsMOJO, with this rating last updated on 09 Mar 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 24 March 2026, providing investors with an up-to-date view of the company’s performance and outlook."
      },
      {
        "title": "Nureca Ltd Valuation Shifts Signal Price Attractiveness Concerns Amid Sector Challenges",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/nureca-ltd-valuation-shifts-signal-price-attractiveness-concerns-amid-sector-challenges-3906254",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/NurecaLtd_valuationdot_3906254.png",
        "date": "2026-03-23 08:01:10",
        "description": "Nureca Ltd, a micro-cap player in the Healthcare Services sector, has seen its valuation metrics shift notably, with its price-to-earnings (P/E) ratio rising to 21.57 and price-to-book value (P/BV) inching up to 1.15. This movement has prompted a downgrade in its Mojo Grade from Hold to Sell as of 9 March 2026, reflecting growing concerns over price attractiveness amid subdued financial performance and sector headwinds."
      },
      {
        "title": "Nureca Ltd Valuation Shifts Signal Changing Price Attractiveness Amid Market Pressure",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/nureca-ltd-valuation-shifts-signal-changing-price-attractiveness-amid-market-pressure-3895627",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/NurecaLtd_valuationdot_3895627.png",
        "date": "2026-03-17 08:01:34",
        "description": "Nureca Ltd, a micro-cap player in the Healthcare Services sector, has recently undergone a notable shift in its valuation parameters, moving from an expensive rating to a fair valuation. Despite this adjustment, the company’s financial performance and market returns continue to pose concerns for investors, reflected in its downgraded Mojo Grade to Sell. This article analyses the valuation changes, compares Nureca’s metrics with peers, and assesses the implications for investors amid a challenging market backdrop."
      },
      {
        "title": "Nureca Ltd Downgraded to Sell Amid Mixed Financials and Bearish Technicals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/nureca-ltd-downgraded-to-sell-amid-mixed-financials-and-bearish-technicals-3882174",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/NurecaLtd_mojoScore_3882174.png",
        "date": "2026-03-10 08:36:12",
        "description": "Nureca Ltd, a player in the healthcare services sector, has seen its investment rating downgraded from Hold to Sell as of 9 March 2026. This shift reflects a combination of deteriorating technical indicators, challenging long-term fundamentals, and valuation concerns despite recent positive quarterly financial results. The company’s current Mojo Score stands at 34.0, with a Sell grade, marking a significant change in investor sentiment."
      }
    ],
    "total": 258,
    "sid": "1003462",
    "stock_news_url": "https://www.marketsmojo.com/news/nureca-1003462"
  },
  "announcements": [
    {
      "caption": "Closure of Trading Window",
      "datetime": "27-Mar-2026",
      "details": "Nureca Limited has informed the exchange regarding Trading Window Closure .",
      "source": "BSE"
    },
    {
      "caption": "Disclosures under Reg. 10(7) of SEBI (SAST) Regulations 2011",
      "datetime": "31-Jan-2026",
      "details": "The Exchange has received the disclosure under Regulation 10(7) in respect of acquisition under Regulation 10(1)(a)(i)of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Saurabh Goyal Aryan Goyal Payal Goyal Smita Goyal & Nectar Biopharma Pvt Ltd",
      "source": "BSE"
    },
    {
      "caption": "Disclosures under Reg. 29(1) & 29(2) of SEBI (SAST) Regulations 2011",
      "datetime": "28-Jan-2026",
      "details": "The Exchange has received the disclosure under Regulation 29(1) & 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Saurabh Goyal & Others",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Nureca Ltd has declared <strong>30%</strong> dividend, ex-date: 24 Feb 22",
          "dt": "2022-02-24",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}
stock newsNews and Views
stock-recommendationAnnouncement

Closure of Trading Window

27-Mar-2026 | Source : BSE

Nureca Limited has informed the exchange regarding Trading Window Closure .

Disclosures under Reg. 10(7) of SEBI (SAST) Regulations 2011

31-Jan-2026 | Source : BSE

The Exchange has received the disclosure under Regulation 10(7) in respect of acquisition under Regulation 10(1)(a)(i)of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Saurabh Goyal Aryan Goyal Payal Goyal Smita Goyal & Nectar Biopharma Pvt Ltd

Disclosures under Reg. 29(1) & 29(2) of SEBI (SAST) Regulations 2011

28-Jan-2026 | Source : BSE

The Exchange has received the disclosure under Regulation 29(1) & 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Saurabh Goyal & Others

stock-recommendationCorporate Actions
Corporate Actions
info
stock-summary
BOARD MEETING

No Upcoming Board Meetings

stock-summary
DIVIDEND

Nureca Ltd has declared 30% dividend, ex-date: 24 Feb 22

stock-summary
SPLITS

No Splits history available

stock-summary
BONUS

No Bonus history available

stock-summary
RIGHTS

No Rights history available